论文部分内容阅读
目的检测慢性心力衰竭(CHF)患者血清中期因子(MK)水平,探讨其临床价值。方法收集CHF患者91例,按照纽约心脏协会(NYHA)心功能分级标准进行分级,其中心功能Ι级22例、Ⅱ级24例、Ⅲ级25例、Ⅳ级20例,同期正常健康体检者血清标本30例,采用酶联免疫吸附(ELISA)法测定血清标本中的MK水平。随访1年,终点事件为全因死亡。结果 CHF患者组血清MK平均水平高于对照组,差异有统计学意义(P<0.05);随着心功能分级增加,血清MK水平逐级升高,各组之间差异有统计学意义(P<0.05);随访1年,死亡组血清MK水平高于非死亡组,差异有统计学意义(P<0.05)。结论血清MK水平能准确、有效地对CHF患者进行诊断,反映心力衰竭的严重程度。高水平的MK预示未来1年心衰患者发生死亡的风险将显著增加。
Objective To detect the level of serum midkine (MK) in patients with chronic heart failure (CHF) and explore its clinical value. Methods Totally 91 CHF patients were enrolled in this study. They were graded according to the New York Heart Association (NYHA) Cardiac Function Grading Scale. Their central function was grade Ι in 22 cases, grade ¢ ò in 24, grade ¢ ó in 25, and grade ¢ ö in 20. Specimens were collected from 30 patients. The level of MK in serum samples was determined by enzyme-linked immunosorbent assay (ELISA). Followed up for 1 year, the end point of all-cause death. Results The mean level of serum MK in patients with CHF was significantly higher than that in controls (P <0.05). With the increase of heart function, the level of serum MK increased step by step and the difference was statistically significant (P <0.05). After one year of follow-up, the level of serum MK in death group was significantly higher than that in non-death group (P <0.05). Conclusions Serum MK levels can accurately and effectively diagnose CHF patients and reflect the severity of heart failure. High levels of MK indicate a significant increase in the risk of death from heart failure in the next year.